Edgewood Management’s Agios Pharmaceuticals AGIO Stock Holding History

Edgewood Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.3M	Hold	35,000	–	–	0.01%	61
2026 Q1	$1.18M	Hold	35,000	–	–	0.01%	65
2025 Q4	$953K	Hold	35,000	–	–	﹤0.01%	68
2025 Q3	$1.4M	Hold	35,000	–	–	0.01%	61
2025 Q2	$1.16M	Hold	35,000	–	–	﹤0.01%	60
2025 Q1	$1.03M	Buy	35,000 +5,000	+17%	+$166K	﹤0.01%	66
2024 Q4	$986K	Hold	30,000	–	–	﹤0.01%	66
2024 Q3	$1.33M	Hold	30,000	–	–	﹤0.01%	59
2024 Q2	$1.29M	Hold	30,000	–	–	﹤0.01%	60
2024 Q1	$877K	Hold	30,000	–	–	﹤0.01%	61
2023 Q4	$668K	Hold	30,000	–	–	﹤0.01%	62
2023 Q3	$743K	Hold	30,000	–	–	﹤0.01%	61
2023 Q2	$850K	Hold	30,000	–	–	﹤0.01%	58
2023 Q1	$689K	Hold	30,000	–	–	﹤0.01%	60
2022 Q4	$842K	Hold	30,000	–	–	﹤0.01%	56
2022 Q3	$848K	Buy	+30,000	New	+$805K	﹤0.01%	53
2022 Q2	–	Sell	-20,000	Closed	-$582K	–	78
2022 Q1	$582K	Buy	+20,000	New	+$611K	﹤0.01%	67

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Edgewood Management's AGIO Position: Q2 2026 in Review

Edgewood Management held its Agios Pharmaceuticals (AGIO) position steady in Q2 2026 at 35,000 shares worth $1.3M. The position accounts for 0.01% of the portfolio, ranked #61.

Edgewood Management first reported a position in AGIO in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.4M in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

Edgewood Management held 35,000 shares of Agios Pharmaceuticals worth $1.3M as of Q2 2026.
Edgewood Management left its Agios Pharmaceuticals share count unchanged in Q2 2026.
Agios Pharmaceuticals made up 0.01% of Edgewood Management's portfolio in Q2 2026, its #61 holding.
Edgewood Management first reported a position in Agios Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
Edgewood Management's Agios Pharmaceuticals position peaked at $1.4M in Q3 2025.
238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Edgewood Management's 13F filing for Q2 2026, filed 13 Aug 2026.